Retinal vascular occlusion and SARS-CoV-2 vaccination

Stela Vujosevic1,2 · Celeste Limoli2,3 · Simona Romano2 · Lucia Vitale2 · Edoardo Villani2,4 · Paolo Nucci1

Received: 10 February 2022 / Revised: 26 April 2022 / Accepted: 14 May 2022 / Published online: 25 May 2022
© The Author(s) 2022

Abstract

Purpose To assess the clinical and retinal imaging features of patients in whom retinal vascular occlusion (VO) had developed in temporal associations with COVID-19 vaccination.

Methods In this retrospective case series, all consecutive adult patients with new onset VO within 6 weeks of vaccination against COVID-19 were included in the study between May 1 and October 31, 2021. All patients had a systemic medical health assessment, full ophthalmic evaluation, and complete fundus imaging.

Results Fifteen eyes of VO (14 patients) after COVID-19 vaccinations were identified. The median time between vaccination and symptoms onset was 14 days (range 7–42 days). The mean best-corrected visual acuity (BCVA) was 20/55 with a range of 20/20 to 20/200. Eleven of 15 eyes (73.3%) had visual acuity improvement after intravitreal treatment at 60–90 days (range, 45–105 days) from the presentation. Four of 5 cases without systemic risk factors for VO had a mean BCVA > 20/32 at presentation and > 20/25 at the latest evaluation.

Between May 1 and October 31, 2021, a temporal association was found between the 15 reported cases and COVID-19 vaccination out of a total of 29 VO (p = 0.05). The incidence of VO was higher in the considered period compared to the incidence of the same 6-month period in 2019 (1.17% vs 0.52%, respectively; p = 0.0134).

Conclusions Retinal vascular occlusion with different grades of severity are reported in temporal association with COVID-19 vaccination. The exact pathogenic mechanism needs to be further studied. No certain causal relationship can be established from this case series.

Key messages

- Unusual thrombotic systemic events after receiving Covid-19 vaccines have been reported in literature.
- In this retrospective case series, we present 15 eyes (14 patients) with retinal vascular occlusion presenting from 1 to 6 weeks after receiving a dose of the Covid-19 vaccine, either vector vaccines or mRNA ones. An increased incidence of retinal vascular occlusion between May 1st and October 31st 2021 was found in comparison to the incidence of the same 6 months’ interval in the pre-pandemic period in 2019.
- Covid-19 vaccinations could result in the rare development of retinal vascular occlusion, however no certain causal relationship can be established from this study design.

Keywords Retinal vascular occlusion · Retinal imaging · COVID-19 · COVID-19 vaccination

Celeste Limoli and Simona Romano contributed equally to this work.

Stela Vujosevic
stela.vujosevic@unimi.it

1 Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
2 Eye Clinic, IRCCS MultiMedica, Milan, Italy
3 University of Milan, Milan, Italy
4 Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy
Introduction

The development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been shown to be the most important countermeasure to curb COVID-19 (coronavirus disease) pandemic. Vaccines have been reported to protect against severe illness from SARS-CoV-2 infection [1–5]. Thus far, four types of COVID-19 vaccines have been approved by the European Medicines Agency: mRNA vaccines, including BNT162b2, Pfizer-BioNTech, and mRNA-1273, Moderna; vector vaccines, including ChAdOx1 nCoV-19/AZD1222, Vaxzevria (ex-Oxford-AstraZeneca) [1–5] and Ad26.COV2, Janssen Johnson & Johnson.

The mass vaccination campaign against SARS-CoV-2 started in Italy on the 27th of December 2020. As of October 2021, the Italian Ministry of Health and Prevention announced that over 45 million people (83.5% of the population) had completed the recommended scheme and were fully vaccinated [6]. The mRNA vaccination is administered in 2-dose series separated by 3 weeks (21 days), the ChAdOx1 in 2-dose series separated by 8–12 weeks, whereas Ad26.COV2 has a single-dose regimen [6].

Given the scale of the current vaccination program, several rare ocular adverse events related to vaccines have been reported and their potential manifestations constitute a safety concern [7].

In this single-center case series, we hereby define the longitudinal characteristics of patients with retinal vascular occlusion (VO) in the temporal context of SARS-CoV-2 vaccinations, focusing on the time lapse between vaccination and disease onset, clinical and imaging features, and short-term outcomes.

A report of such ocular adverse events is timely and would be beneficial to design and implement protocols for close monitoring of patients that may be at higher risk.

Methods

All consecutive adult patients with new onset retinal VO within 6 weeks of vaccination against COVID-19 who presented to the Medical Retina & Imaging Service at the University Eye Clinic San Giuseppe Hospital, Milan, Italy, between May 1, 2021, and October 31, 2021, were included in this retrospective case series study.

The diagnosis of VO was based on a comprehensive ophthalmic examination, best-corrected visual acuity determination (BCVA); slit lamp evaluation, intraocular pressure (IOP), dilated funduscopy, optical coherence tomography (OCT) and OCT angiography (OCT-A) (Heidelberg Spectralis HRA-OCT; Heidelberg Engineering, Heidelberg, Germany), ultra-wide field fundus color photo, and fluorescein angiography (FFA) (Optos California, Optos PLC, Dunfermline, UK).

Different types of VO had been diagnosed, including central retinal artery occlusion (CRAO), branch retinal artery occlusion (BRAO), and retinal vein occlusion (RVO), classified as central retinal vein occlusion (CRVO), hemiretinal vein occlusion (HRVO), and branch retinal vein occlusion (BRVO) [8]. Blood test including basic metabolic panel, complete blood count, coagulation tests like activated partial thromboplastin time (aPTT), thrombin time (TT) and prothrombin time (PT), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fibrinogen, and homocysteine excluded thrombotic risk or underlying hematologic disease with possible influence on the onset of RVO.

ECG and carotid ultrasound were also performed to uncover any possible additional risk factors. In the younger patient, also factor V Leiden gene mutation, factor VIII activity, protein S activity, and antithrombin III (AT III), antinuclear antibodies (ANA), lupus anticoagulant, and anticardiolipin antibodies were tested.

No other concurrent ocular conditions were present at the time of the diagnosis. Patients provided proof of a negative COVID-19 test that met performance standards, either as an antigen or nucleic acid amplification tests [9].

Vaccination data by November 2021 including the delivered number of vaccine doses, types, and presence of ocular adverse event post COVID-19 vaccination in Italy are provided in Table 1 [7, 10].

To investigate the possible temporal association between COVID-19 vaccines and VO, we counted and confronted the new cases of VO presenting to our Medical Retina & Imaging Service occurred within 6 weeks of vaccination and the cases occurred beyond 6 weeks in the inclusion period (May 1 to October 31, 2021). In addition, we compared the incidence of VO of this period to the equivalent period prior to the onset of COVID-19 pandemic (May 1 to October 31, 2019).

The study was approved by the Ethics Committee of IRCCS MultiMedica and adhered to the Tenets of the Declaration of Helsinki. Each patient gave informed consent for use of data.

Statistical analysis  Categorical variables were reported with number and percentage, and continuous variables were summarized with mean and range. Univariate comparison between groups of VO patients was performed using the Fisher’s exact test. A log-linear analysis was applied to compare the proportions of the different categorical variables among the three groups, one-way analysis of variance (ANOVA) was applied to compare the means of numerical variables (age and BCVA) followed by Bonferroni post hoc analysis.

Springer
A p value \leq 0.05 was considered significant. The data analysis was performed using SPSS Statistics version 28 (IBM).

Results

Fifteen cases of VO (14 patients) in temporal association with SARS-CoV-2 vaccinations (BNT162b2 n = 8, ChAdOx1 n = 6, Ad26.COV2 n = 1) were identified.

Six cases (40%) occurred after the first ChAdOx1 dose (Vaxzevria), 8 cases (53.3%) were noted following the second BNT162b2 dose (Pfizer), and 1 case (6.6%) after Ad26.COV2 (Janssen). No cases were reported after mRNA-1273 (Moderna). The median time between vaccination and symptoms onset was 14 days (range 7–42 days).

Characteristics of all 14 patients are presented in Table 2.

In the present case series, women were affected slightly more often than men (9 (64.2%) versus 5 (35.7%), respectively); the median age was 77 years (range, 40 to 96).

Nine patients (64.2%) met the criteria for classic risk factors for RVO. More specifically, 7 (50%) patients had systemic hypertension (HTN), 4 (28.5%) had hyperlipidemia (HL), 3 (21.4%) had diabetes mellitus type 2 (T2DM), where 6 (42.8%) patients had 2 of these risk factors and 1 (7.1%) had all 3.

One patient (7.1%) had a previous ocular history of BRVO in the fellow eye. Four patients (28.5%) had negative medical history.

Unilateral acute vision loss was the most common presenting symptom; 1 patient (7.1%) presented with bilateral vision loss. The mean BCVA was 20/55 with a range of 20/20 to 20/200. The most severely affected eyes (patients with VO) had a mean BCVA of 20/32 at presentation and showed limited improvement at latest follow-up (range, 45–105 days).

Four of 5 cases with no associated systemic risk factors for VO had a mean BCVA > 20/32 at presentation and > 20/25 at the latest evaluation.

A spectrum of severity of clinical findings found at presentation is outlined in Table 2.

VO included CRVO in 5 (33.3%) eyes, HRVO in 2 (13.3%) eyes, BRVO in 7 (46.6%) eyes, and 1 (6.6%) eye with central retinal artery occlusion (CRAO).

Treatment included administration of intravitreal anti-vascular endothelial growth factor (VEGF) in 1 (6.6%) eye, the use of a sustained-release intravitreal dexamethasone implant in 7 (46.6%) eyes, whereas 2 (13.3%) eyes required retinal laser photocoagulation due to extensive ischemia, not in association with anti-VEGF injections.

Overall, 11 eyes (73.3%) had visual acuity improvement 2–3 months (range, 45–105 days) from the presentation; however, 4 (26.6%) eyes did not achieve any BCVA recovery from the presentation. Although the follow-up was relatively short, there has been no recurrence of RVO.

In addition to the 15 cases of VO identified in temporal association with COVID-19 vaccination (< 6 weeks), other 14 cases of VO not related to vaccination (> 6 weeks) occurred, for a total of 29 cases of VO presented at our Medical Retina Service from May 1 to October 31, 2021.

We found a statistically significant temporal association of the 15 reported cases with COVID-19 vaccination (p = 0.05), as they occurred within 6 weeks of vaccination and the remaining 14 cases occurred beyond that period (out of a total of 26 weeks).

Finally, between May 1 and October 31, 2021, there were 2470 cases visited at the Medical Retina Service, with an estimated incidence of VO of 1.17% cases. In the same temporal interval in 2019, there were 2671 cases of which 14 cases with VO (0.52%) visited at the same Medical Retina Service. The incidence of newly diagnosed VO was significantly higher in 2021 vs those in 2019, before the COVID-19 pandemic, p = 0.0134.

Tables 3 and 4 describe demographic data, clinical features, treatments, and outcomes of patients with VO in pre-pandemic period and those with VO occurred beyond 6 weeks from vaccination during the COVID-19 pandemic, respectively. No statistically significant differences were found in either studied clinical variables among the three different groups.

Table 1 Vaccination data by November 2021 in Italy and presence of ocular adverse event post COVID-19 vaccination

| Type of vaccine | Number of delivered doses | Ocular adverse event (total of reported adverse event) |
|-----------------|---------------------------|-------------------------------------------------------|
| Total           | 99,797,303                | 1716 (114,279) (1.5%)                                  |
| BNT162b2 (Pfizer) | 71,173,035                | 2 (163) (1.2%)                                         |
| mRNA-1273 (Moderna) | 15,233,690          | 443 (31,272) (1.4%)                                    |
| Ad26.COV2 (Janssen) | 1,846,027                | 89 (4135) (0.2%)                                       |
| ChAdOx1 (Vaxzevria) | 11,544,551              | 1182 (78,709) (1.5%)                                   |

Data (through September 26, 2021) summarized from: Agenzia Italiana del Farmaco. Available at: https://bi.aifa.gov.it/SASVisualAnalyticsViewer/VisualAnalyticsViewer_guest.jsp?reportName=FVGV_ Intro0_report&reportPath=\Shared+Data\B14+FARMACOVIG ILANZA/Public/Report&appSwitcherDisabled=true [7]

Data on delivered vaccine doses were retrieved from https://www.governo.it/it/cscovid19/report-vaccini/ [10]
| Patient No | Age (years) | Sex | Medical history | Vaccine type | Dose given | Time from vaccine to symptoms | Visual acuity at diagnosis of vasculitis | Vascular occlusion features | Laterality | IOI Edema | Hemorrhages | Ischemia | Neovascularization | Vitreous Treatment | Visual acuity at latest evaluation |
|-----------|-------------|-----|-----------------|--------------|------------|-------------------------------|----------------------------------------|---------------------------------|------------|-----------|-------------|----------|-----------------|------------------------|---------------------------------|
| 1         | 69          | F   | DVT             | ChAdOx1      | I          | 1 week                        | 20/32                                  | Inferotemporal BRVO               | RE         | -         | +           | Quadrant | No              | No                     | Laser photo-coagulation            | 20/20                  |
| 2         | 82          | F   | None            | BNT162b2     | II         | 2 weeks                       | 20/63                                  | Inferotemporal BRVO               | RE         | -         | ++         | Quadrant | No              | No                     | Steroid treatment               | 20/40                  |
| 3         | 96          | F   | HTN T2DM        | BNT162b2     | II         | 1 week                        | 20/200                                 | CRVO                            | RE         | -         | ++, SND     | No       | No              | No                     | Steroid treatment               | 20/200                 |
| 4         | 91          | F   | None            | BNT162b2     | II         | 1.5 weeks                     | CRVO                                  | LE                              | +          | ++        | +++        | No       | No              | No                     | Patient refused               | CF                      |
| 5         | 78          | F   | None            | BNT162b2     | II         | 1 week                        | 20/25                                  | Supertemporal BRVO               | RE         | -         | +          | No       | No              | No                     | Anti-VEGF agents              | 20/20                  |
| 6         | 70          | M   | None            | ChAdOx1      | I          | 1 week                        | 20/20                                  | CRVO                            | RE         | -         | ++          | No       | No              | No                     | None                            | 20/20                  |
| 7         | 40          | M   | Hyperhomocysteinemia | ChAdOx1 | I          | 2 weeks                       | 20/20                                  | BRVO                            | RE         | -         | +          | No       | No              | No                     | None                            | 20/20                  |
| 8         | 76          | M   | HTN T2DM        | ChAdOx1      | I          | 6 weeks                       | 20/32                                  | CRAO                            | RE         | -         | -           | No       | No              | No                     | None                            | CF                      |
| 9         | 91          | M   | None            | BNT162b2     | II         | 4 weeks                       | 20/32                                  | BRVO                            | RE         | -         | ++, SND    | No       | No              | No                     | Steroid treatment               | 20/32                  |
| 10        | 72          | F   | HTN HL          | BNT162b2     | II         | 3 weeks                       | 20/25                                  | Supertemporal BRVO               | RE         | -         | +          | Quadrant | No              | No                     | Steroid treatment               | 20/20                  |
Table 2 (continued)

| Patient No | Age (years) | Sex | Medical history | Vaccine type | Dose given | Time from vaccine to symptoms | Visual acuity at diagnosis of vasculits | Vascular occlusion features | Laterality | IOI Edema | Hemorrhages | Ischemia | Neovascularization | Vitreous Treatment | Visual acuity at latest evaluation |
|------------|-------------|-----|-----------------|--------------|------------|-------------------|------------------------------------|---------------------------------|-----------|-----------|-------------|----------|----------------|------------------|----------------------------------|
| 11         | 88          | M   | HTN, CVD, Alzheimer | BNT162b2     | II         | 2 weeks            | 20/125                             | HRVO, RE                       | -         | ++        | +           | No       | No            | No               | Steroid treatment               | 20/125                  |
| 12         | 73          | F   | HTN, CVD, NET      | ChAdOx1      | II         | 4 weeks            | CF                                 | CRVO, RE                       | -         | +         | ++          | No       | No            | Yes              | Steroid treatment               | CF                      |
| 13         | 65          | F   | HTN, T2DM, COV2    | Ad26. COV2   | I          | 1 week             | 20/40                              | CRVO, RE                       | -         | +         | ++          | No       | No            | No               | Steroid treatment               | 20/32                   |
| 14         | 72          | F   | HTN, CVD           | ChAdOx1      | I          | 2 weeks            | 20/50                              | HRVO, LE                       | -         | -         | ++          | No       | No            | No               | Laser photocoagulation            | 20/50                   |

*RE* right eye, *LE* left eye, *IOI* intraocular inflammation, *F* female, *M* male, *DVT* deep vein thrombosis, *HTN* hypertension, *T2DM* type 2 diabetes mellitus, *HL* hyperlipidemia, *CVD* cardiovascular disease, *NET* neuroendocrine tumor, *CRVO* central retinal vein occlusion, *HRVO* hemiretinal vein occlusion, *BRVO* branch retinal vein occlusion, *CRAO* central retinal artery occlusion, *CF* counting fingers, *SND* subfoveal neuroretinal detachment.
In the 6-month inclusion period (May 1, 2021–October 31, 2021), we found a temporal association between the 15 reported cases and COVID-19 vaccination out of a total of 29 VO. In addition, an increased incidence of VO between May 1 and October 31, 2021, was found in comparison to the incidence of the same 6-month interval in 2019. Therefore, these findings could foster the temporal association between COVID-19 vaccination and VO to explain the increase in the number of patients presenting with VO in the short period of time noted above.

The occurrence of ocular adverse events after SARS-CoV-2 immunization is rare, as reported on a monthly basis by AIFA in Italy [10], and is presented in Table 1. Retinal vascular adverse events after COVID-19 vaccinations appear to be rare [11]. However, there is now a growing literature reporting single case reports with RVO after both mRNA vaccines including mRNA-1273 (Moderna) [12] and BNT162b2 (Pfizer) [13–16], and vector-based ChAdOx1 (Vaxzevria) [17–19]. Other single case reports have documented combined CRAO-CRVO shortly after mRNA-1273 (Moderna) [20], combined CRAO-CRVO with ischemic optic neuropathy after BNT162b2 (Pfizer) [21], and CRAO after ChAdOx1 (Vaxzevria) [22].

Besides the reported ophthalmic cases, unusual thrombotic systemic events after COVID-19 vaccines, including ChAdOx1 nCoV-19 (Vaxzevria), Ad26.COV2.S (Janssen) [23–31], have increasingly been reported in literature. The condition is described as COVID-19 vaccine-related thrombosis and thrombocytopenia, namely thrombosis with thrombocytopenia syndrome (TTS).

Three separate case series have described patients who developed TTS after ChAdOx1 vaccination (Vaxzevria) [23–25]. TTS, which clinically simulate heparin-induced thrombocytopenia, is mediated by platelet-activating antibodies against platelet factor 4 (PF4) [26] and, interestingly, is more frequently observed following the first dose of ChAdOx1 (Vaxzevria) [23–25]. Furthermore, it has been noted that TTS manifest at 1- to 4-week period post-vaccination, which corresponds to the time for mounting a secondary antibody response [26, 27]. Similar hematological findings have been reported after Ad26.COV2 vaccination (Janssen) [28], which is an adenoviral-based vaccine like the ChAdOx1 (Vaxzevria).

To investigate the association between COVID-19 vaccines and hematological and vascular adverse events, a Scottish national population-based prospective cohort study has been conducted [29]. Positive associations were seen between the first-dose of ChAdOx1 (Vaxzevria) and idiopathic thrombocytopenic purpura as well as venous, arterial thromboembolic, and hemorrhagic events [29]. BNT162b2 (Pfizer), by contrast, did not show a statistically significant association with the aforementioned adverse events [29]. Interestingly, our findings of RVO occurrence after the first dose of ChAdOx1 are consistent with the results of these studies.

Therefore, it may be tempting to suggest a common pathogenic pathway of these thromboembolic events, linking the interaction of adenoviral-based vaccine vector versus SARS-CoV-2 with PF4 and other specific host proteins and the contribution to rare adverse events like RVO.

With regard to mRNA-based vaccines, it remains still unknown the pathogenic pathway underlying the observed vascular adverse events. Further studies are needed to investigate it and if there is any common pathogenic mechanism already described for ChAdOx1.

To the best of our knowledge, this is the first case series to report the temporal association between COVID-19 vaccination and VO. Our analysis showed that more cases were reported after mRNA-based vaccine Pfizer, followed by adenovirus vector-based DNA vaccines, Vaxzevria and Janssen. The lack of cases after mRNA-based vaccine Moderna could be deemed due to the smaller number of given doses in Italy at the time of the analysis [7]. However, similar levels of effectiveness and safety profile of both the mRNA-based vaccines were found in real-world use in Italy [10].

The clinical course of the VO had a range in the severity of findings; most patients responded well to therapy or recovered spontaneously, and visual acuity was preserved. Of note, 4 of 5 cases without risk factors for RVO had good final visual outcome.

VO presumably related to SARS-CoV-2 vaccination is an entity that apparently shares several features with the typical VO. These ocular findings seem to overlap with ophthalmic manifestations induced by COVID-19 itself, implying a common pathogenetic pathway between SARS-CoV-2 virus and vaccine-mediated immune response [30]. The pathogenesis of abnormalities in the retina subsequent to COVID-19 vaccinations could be explained by immunologic response elicited by components of the vaccine (spike antigen, other viral epitopes, human, or chimpanzee adenoviral components), and by molecular mimicry, where the vaccine components share structural similarities with self-antigens leading to an immunological self-tolerance break and an autoimmune response [31].

In this context, the pathogenic mechanism of VO after COVID-19 vaccination has not been elucidated and it is important to emphasize that no certain causality can be established from this case-series.

However, we need to acknowledge that the study was single-center, the design retrospective, and these results might also be attributed to other neglected variables, including the closure of private eye clinics diverting cases to our tertiary referral center during the pandemic and the likely increase of cardiovascular related events as an indirect effect of COVID-19 pandemic restrictions.
Table 3  Details on demographics, clinical features, treatment, and outcome of patients with VO in pre-pandemic period (2019)

| Patient No | Age (years) | Sex | Medical History | Visual Acuity at Diagnosis of Vasculitis | Vascular Occlusion Features | Laterality | IOI | Edema | Hemorrhages | Ischemia | Neovascularization | Vitreous | Treatment | Visual Acuity at Latest Evaluation |
|------------|-------------|-----|-----------------|-----------------------------------------|-----------------------------|------------|-----|-------|-------------|----------|---------------------|----------|-----------|----------------------------------|
| 1          | 81          | M   | CVD, HTN        | 20/200                                  | CRVO                        | LE         | +   | +     | +           | +        | No                  | No       | Steroid treatment    | 20/50    |
| 2          | 81          | F   | None            | 20/40                                   | Supero-temporal BRVO        | RE         | -   | +     | -           | -        | No                  | No       | Anti-VEGF agents      | 20/63    |
| 3          | 73          | M   | HTN, HL         | 20/32                                   | BRVO                        | LE         | -   | -     | +           | +        | No                  | No       | Laser photocoagulation | 20/25    |
| 4          | 55          | F   | HTN             | 20/25                                   | HRVO                        | LE         | -   | -     | +           | -        | No                  | No       | None                  | 20/20    |
| 5          | 69          | M   | HTN, HL         | CF                                      | CRVO                        | RE         | -   | -     | +           | +        | No                  | No       | Laser photocoagulation | CF       |
| 6          | 72          | M   | Ulcerative colitis, antiaggregant therapy | 20/40 | Supero-temporal BRVO | RE | - | + | + | ± | No | No | Anti-VEGF agents | 20/25 |
| 7          | 62          | F   | HTN, antiaggregant therapy | 20/50 | HRVO | LE | - | + | + | + | No | No | None | Missing data |
| 8          | 70          | F   | HTN             | CF                                      | CRVO                        | LE         | -   | +     | +           | +        | No                  | No       | Steroid treatment    | CF       |
| 9          | 85          | F   | HTN, antiaggregant therapy | CF | CRVO | RE | - | + | + | + | No | No | Steroid treatment | 20/100 |
| 10         | 72          | F   | Antiaggregant therapy | 20/25 | BRAO | LE | - | - | - | + | No | No | None | 20/20 |
| 11         | 83          | F   | CVD             | CF                                      | Supero-temporal BRVO        | LE         | -   | -     | +           | +        | No                  | No       | Missing data          | Missing data |
| 12         | 79          | M   | HTN, T2DM       | 20/100                                  | CRVO                        | RE         | +   | +     | -           | -        | No                  | No       | Anti-VEGF agents      | 20/100   |
| 13         | 81          | M   | HTN             | Missing data                            | CRVO                        | RE         | -   | -     | +           | -        | No                  | No       | None                  | Missing data |
| 14         | 72          | F   | Oral antiaggregant therapy | CF | CRVO | RE | + | - | + | - | No | ± | No | 20/100 |

*RE* right eye, *LE* left eye, *IOI* intraocular inflammation, *F* female, *M* male, *HTN* hypertension, *T2DM* type 2 diabetes mellitus, *HL* hyperlipidemia, *CVD* cardiovascular disease, *CRVO* central retinal vein occlusion, *HRVO* hemiretinal vein occlusion, *BRVO* branch retinal vein occlusion, *CRAO* central retinal artery occlusion, *CF* counting fingers
Table 4  Details on demographics, clinical features, treatment and outcome of patients with VO occurred beyond 6 weeks from vaccination during the COVID-19 pandemic

| Patient No | Age (years) | Sex | Medical history | Visual acuity at diagnosis of vasculitis | Vascular occlusion features | Laterality | IOI | Edema | Hemorrhages | Ischemia | Neovascularization | Vitreous | Treatment | Visual acuity at latest evaluation |
|------------|-------------|-----|----------------|------------------------------------------|-----------------------------|------------|-----|-------|-------------|----------|---------------------|---------|-----------|----------------------------------|
| 1          | 75          | F   | HTN, HL, antiaggregant therapy | 20/160 | CRVO | RE | - | + + + | + | + | No | No | Anti-VEGF agents, laser photocoagulation | 20/160 |
| 2          | 89          | F   | HTN, oral anticoagulant therapy | 20/32 | Combined superotemporal BRAO + BRVO | RE | - | - | + | + | No | No | None | 20/20 |
| 3          | 63          | M   | None | 20/160 | CRVO | LE | - | + | + | + | No | No | Anti-VEGF agents, laser photocoagulation | CF |
| 4          | 61          | M   | None | 20/20 | BRVO | LE | - | - | +/- | - | No | No | None | 20/20 |
| 5          | 50          | F   | None | 20/100 | BRVO | LE | - | + | + | ± | No | No | Steroid treatment | 20/32 |
| 6          | 85          | F   | HTN, hypothyroidism | 20/63 | BRVO | LE | - | + + | + | - | No | No | Anti-VEGF agents | 20/63 |
| 7          | 80          | F   | None | 20/32 | Inferotemporal BRVO | RE | - | + + | + | - | No | No | Steroid treatment | 20/63 |
| 8          | 70          | F   | 2TDM | 20/16 | BRVO | RE | - | + + | + | - | No | No | Anti-VEGF agents | 20/25 |
| 9          | 86          | F   | HTN, CVD | 20/100 | Superotemporal BRVO | LE | - | - | + | + | No | No | Laser | CF |
| 10         | 58          | F   | HTN | 20/25 | Inferior BRVO | RE | - | Small SND | + | + | No | No | None | 20/20 |
| 11         | 70          | F   | 2TDM | 20/160 | CRVO | RE | - | + + + | SND | + | - | No | No | Steroid treatment | 20/160 |
| 12         | 86          | F   | HTN, breast cancer | 20/32 | HRVO | LE | - | - | + | - | No | No | None | 20/32 |
| 13         | 49          | F   | HTN | 20/25 | CRVO | RE | - | - | + | - | No | No | None | 20/20 |
| 14         | 75          | M   | 2TDM | 20/40 | Super-temporal BRVO | LE | - | - | + | + | No | No | Laser photocoagulation | 20/25 |

*RE right eye, LE left eye, IOI intraocular inflammation, F female, M male, HTN hypertension, T2DM type 2 diabetes mellitus, HL hyperlipidemia, SND subfoveal neuroretinal detachment, CVD cardiovascular disease, CRVO central retinal vein occlusion, HRVO hemiretinal vein occlusion, BRVO branch retinal vein occlusion, CRAO central retinal artery occlusion, CF counting fingers
Finally, one important issue concerns the presumable time period of cause-effect relationship between vaccination and RVO. In this case series, this interval was set to 6 weeks, in reasonable accordance with available data and established knowledge linking vaccines with vascular or autoimmune conditions [32].

Considering the massive rollout vaccination campaign and the well-established excellent safety profile related to vaccines, it is important to highlight the very low incidence and the well-established excellent safety profile related to conditions [32].

Incidence of ocular adverse events after vaccination appears to be rare but should prompt a thorough ophthalmic evaluation.

Therefore, physicians should consider VO if patients present with vision loss within 6 weeks from COVID-19 vaccination.

Incidence of ocular adverse events after vaccination appears to be rare but should prompt a thorough ophthalmic evaluation.

Funding Open access funding provided by Università degli Studi di Milano within the CRUI-CARE Agreement.

Declarations

Ethics approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethics Committee of IRCCS MultiMedica and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Consent to participate Informed consent was obtained from all individual participants included in the study.

Conflict of interest The authors declare no competing interests.

References

1. Polack FP, Thomas SJ, Kitchin N et al (2020) Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 383:2603–2615
2. Baden LR, El Sahly HM, Essink B et al (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384:403–416
3. Sadoff J, Gray G, Vandeboch A et al (2021) Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med 384(23):2187–2201
4. Voysey M, Clemens SAC, Madhi SA et al (2021) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397(10269):99–111
5. Gao Q, Bao L, Mao H et al (2020) Development of an inactivated vaccine candidate for SARS-CoV-2. Science 369(6499):77–81
6. Report Vaccini Anti COVID-19. Accessed 1 Nov 2021. https://www.governo.it/it/ccs covid19/report-vaccini/
7. Sistema di accesso online ai dati delle segnalazioni di sospette reazioni adverse registrate nella Rete Nazionale di Farmacovigilanza, Agenzia Italiana del Farmaco. Accessed 1 Nov 2021. https://bi.aifa.gov.it/SASVisualAnalyticsViewer/VisualAnalyticsViewer_guest.jsp?reportName=FVG_Intro0_report&reportPath=/Shared+Data/B1+FARMACOVIGILANZA/Public/Report&appSwitcherDisabled=true
8. Hayreh SS (2005) Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res 24(4):493–519
9. Centers for Disease Control and Prevention. COVID-19 testing overview. Updated March 17, 2021. Accessed 1 Nov 2021. https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/testing.html
10. Rapporto sulla Sorveglianza dei vaccini COVID-19, Agenzia Italiana del Farmaco. Accessed 1 Nov 2021. https://www.aifa.gov.it/documents/20142/1315190/Rapporto_sorveglianza_vaccini_COVID-19_9.pdf
11. Zhou JQ, Xu L, Wang S et al (2013) The 10-year incidence and risk factors of retinal vein occlusion: the Beijing eye study. Ophthalmology 120(4):803–808
12. Sacconi R, Simona F, Forte P et al (2022) Retinal vein occlusion following two doses of mRNA-1237 (moderna) immunization for SARS-cov-2: a case report. Ophthalmol Ther 11(1):453–458
13. Endo B, Bahamoon S, Martínez-Pulgarín D (2021) Central retinal vein occlusion after mRNA SARS-CoV-2 vaccination: a case report. Indian J Ophthalmol 69(10):2865–2866
14. Białasiewicz AA, Farah-Diab MS, Mekbarki HT (2021) Central retinal vein occlusion occurring immediately after 2nd dose of mRNA SARS-CoV-2 vaccine. Int Ophthalmol 41(12):3889–3892
15. Shah PP, Gelnick S, Jonisch J, et al. Central retinal vein occlusion following BNT162b2 (Pfizer-BioNTech) COVID-19 messenger RNA vaccine. Retin Cases Brief Rep
16. Pur DR, Catherine Danielle Bursztyn LL, Iordanou Y (2022) Branch retinal vein occlusion in a healthy young man following mRNA COVID-19 vaccination. Am J Ophthalmol Case Rep 26:101445
17. Park HS, Byun Y, Byron SH et al (2021) Retinal hemorrhage after SARS-CoV-2 vaccination. J Clin Med 10(23):5705
18. Peters MC, Cheng SSH, Sharma A et al (2022) Retinal vein occlusion following COVID-19 vaccination. Clin Exp Ophthalmol. Ahead of print
19. Sonawane N, Yadav D, Kota A et al (2022) Central retinal vein occlusion post-COVID-19 vaccination. Indian J Ophthalmol 70(1):308–309
20. Ikegami Y, Numaga J, Okano N et al (2022) Combined central retinal artery and vein occlusion shortly after mRNA-SARS-CoV-2 vaccination. QJM 114(12):884–885
21. Lee S, Sankhala KK, Bose S et al (2022) Combined central retinal artery and vein occlusion with ischemic optic neuropathy after COVID-19 vaccination. Int Med Case Rep J 15:7–14
22. Abdin AD, Gärtner BC, Seitz B (2022) Central retinal artery occlusion following COVID-19 vaccine administration. Am J Ophthalmol Case Rep. 26:101430. https://doi.org/10.1016/j.ajoc.2022.101430
23. Greinacher A, Thiele T, Warkentin TE et al (2021) Thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med 384(22):2092–2101
24. Schultz NH, Sørvoll IH, Michelsen AE et al (2021) Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med 384(22):2124–2130
25. Scully M, Singh D, Lown R et al (2021) Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 384(23):2202–2211
26. Baker AT, Boyd RJ, Sarkar D, et al (2021) ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome. Sci Adv 7(49):eabf8213
27. Greinacher A, Selleng K, Palankar R et al (2021) Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. Blood 138(22):2256–2268
28. Muir KL, Kallam A, Koepsell SA et al (2021) Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. N Eng J Med 384:1964–1965
29. Simpson CR, Shi T, Vasilieou E et al (2021) First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. Nat Med 27(7):1290–1297
30. Ng XL, Betzler BK, Testi I et al (2021) Ocular adverse events after COVID-19 vaccination. Occl Immunol Inflamm 24:1–9
31. Jampol LM, Tauscher R, Schwarz HP (2021) COVID-19, COVID-19 vaccinations, and subsequent abnormalities in the retina: causation or coincidence? JAMA Ophthalmol 139(10):1135–1136
32. Vadala M, Poddighe D, Laurino C, et al (2017) Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon? 8(3):295–311

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.